Ogusu, Shinsuke
Harutani, Yuhei
Tozuka, Takehiro
Saito, Ryota
Koyama, Junji
Sakamoto, Hiroaki
Sonoda, Tomoaki
Tsuchiya-Kawano, Yuko
Oba, Tomohiro
Kudo, Keita
Gyotoku, Hiroshi
Nakatomi, Katsumi
Ariyasu, Ryo
Article History
Received: 28 April 2023
Accepted: 13 August 2023
First Online: 28 August 2023
Declarations
:
: T. Tozuka reports honoraria from Chugai Pharmaceuticals, Astra Zeneca, outside the submitted work, Y Tsuchiya-Kawano reports honoraria from Chugai Pharmaceuticals, Bristol Myers Squib, Astra Zeneca, Ono Pharmaceutical, Kyowa Hakko Kirin, Taiho Pharmaceutical, outside the submitted work, R. Ariyasu reports honoraria from Chugai Pharmaceuticals, Bristol Myers Squib, Astra Zeneca, outside the submitted work. The remaining authors have no conflicts of interest to declare.
: Informed consent was waived because of the retrospective nature of the study, with an opt-out option included.
: This study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and those for medical and health research involving human participants. This study was approved by the institutional review board of the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (IRB No. 2022-GB-065).